COVID-19 Vaccine Hesitancy Driven by Safety, Trust Concerns
The analysis led by epidemiologist Wendy King also found that people in certain occupations report five-fold higher rates of hesitancy than others.
The analysis led by epidemiologist Wendy King also found that people in certain occupations report five-fold higher rates of hesitancy than others.
Women who experience an accelerated accumulation of abdominal fat during menopause are at greater risk of heart disease, even if their weight stays steady, according to a University of Pittsburgh Graduate School of Public Health-led analysis published today in the journal Menopause.
When we hear about clinical trials, we might picture doctors and patients partnering to test new therapies. What we might not think about are the teams of other professionals and scholars who make those studies happen and figure out what the results mean.
EDC Faculty Wendy King publishes work that could help guide clinicians and policymakers in counseling bariatric surgery patients to improve their quality of life for many years to come.
Glaucoma is the leading cause of irreversible blindness in the world. The condition causes damage to the optic nerve resulting in slow, painless vision loss over many years.
The National Institutes of Health (NIH) has selected the University of Pittsburgh to lead a trio of Phase 3 clinical trials involving COVID-19 patients. Collectively known as ACTIV-4 Antithrombotics, these trials will explore the use of blood thinners in saving lives and improving care, particularly among adult COVID-19 patients who are at risk of developing life-threatening blood clots.
The National Eye Institute (NEI) funded the study “Clarifying the Optimal Application of SLT (COAST)” will compare standard SLT to low energy SLT and will also compare retreatment performed as needed when the effect wears off to retreatment annually to maintain eye pressure control without the need for medical therapy.
Dr. Balasubramani has been to the International society for Influenza and other Respiratory Diseases (ISIRV) for a three-year period.